Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 66, No 4 (2016)
Review paper
Published online: 2016-12-23
View PDF Download PDF file View HTML
Get Citation

Locally advanced pancreatic cancer — new therapeutic challenges

Michał Piątek, Sergiusz Nawrocki
DOI: 10.5603/NJO.2016.0059
·
Nowotwory. Journal of Oncology 2016;66(4):312-316.

open access

Vol 66, No 4 (2016)
Review article
Published online: 2016-12-23

Abstract

The overall survival rate of patients with pancreatic ductal adenocarcinoma remains extremely poor, and the only potentially curative treatment is radical surgery. There are three subgroups among the patients: primary resectable, metastatic and locally advanced pancreatic cancer. The term of locally ad advanced pancreatic cancer includes borderline resectable pancreatic cancer (BRPC) and unresectable pancreatic cancer (URPC). As in the case of BRPC, the strategy of induction treatment may convert the inoperable tumour into a resectable one. As in the case of URPC, the optimal standard of treatment is unknown. Recent advances in systemic treatment such as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel as well as the optimisation of local treatment such as stereotactic radiotherapy (SBRT — stereotactic body radiation therapy) should be incorporated into future trials dedicated for BRPC and URPC.

Abstract

The overall survival rate of patients with pancreatic ductal adenocarcinoma remains extremely poor, and the only potentially curative treatment is radical surgery. There are three subgroups among the patients: primary resectable, metastatic and locally advanced pancreatic cancer. The term of locally ad advanced pancreatic cancer includes borderline resectable pancreatic cancer (BRPC) and unresectable pancreatic cancer (URPC). As in the case of BRPC, the strategy of induction treatment may convert the inoperable tumour into a resectable one. As in the case of URPC, the optimal standard of treatment is unknown. Recent advances in systemic treatment such as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel as well as the optimisation of local treatment such as stereotactic radiotherapy (SBRT — stereotactic body radiation therapy) should be incorporated into future trials dedicated for BRPC and URPC.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

BRPC, URPC, FOLFIRINOX, gemcitabine plus nab-paclitaxel, SBRT

About this article
Title

Locally advanced pancreatic cancer — new therapeutic challenges

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 4 (2016)

Article type

Review paper

Pages

312-316

Published online

2016-12-23

Page views

866

Article views/downloads

1490

DOI

10.5603/NJO.2016.0059

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(4):312-316.

Keywords

BRPC
URPC
FOLFIRINOX
gemcitabine plus nab-paclitaxel
SBRT

Authors

Michał Piątek
Sergiusz Nawrocki

References (50)
  1. Ries LAG, Melbert D, Krapcho M et al. SEER cancer statistics review 1975–2004; based on November 2006 SEER data submision. Bethesda; MD National Cancer Institute, 2007.
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4): 225–249.
    CrossRefPubMed
  3. Edge SB, Byrd DR, Compton CC. eds. AJCC cancer staging manual. 7 th ed. Springer, New York 2010.
  4. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014; 146(1): 291–304.
    CrossRefPubMed
  5. Kuhlmann KFD, de Castro SMM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004; 40(4): 549–558.
    CrossRefPubMed
  6. Bassi C, Stocken DD, Olah A, et al. European Study Group for Pancreatic Cancer (ESPAC), European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001; 234(6): 758–768.
    PubMed
  7. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000; 4(6): 567–579.
    PubMed
  8. Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006; 93(10): 1232–1237.
    CrossRefPubMed
  9. Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007; 246(1): 52–60.
    CrossRefPubMed
  10. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297(3): 267–277.
    CrossRefPubMed
  11. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6): 2403–2413.
    CrossRefPubMed
  12. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691–1703.
    CrossRefPubMed
  13. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
    CrossRefPubMed
  14. Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013; 42(8): 1311–1315.
    CrossRefPubMed
  15. Blazer M, Wu CY, Goldberg R, et al. Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC). Journal of Clinical Oncology. 2014; 32(3_suppl): 275.
    CrossRef
  16. Gunturu K, Thumar J, Hochster H, et al. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal of Clinical Oncology. 2012; 30(4_suppl): 330.
    CrossRef
  17. Metges J, Ramée J, Douillard JY, et al. Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 2014; 32(3_suppl): 305.
    CrossRef
  18. Alessandretti M, Moreira R, Brandao E, et al. Safety and efficacy of modified dose-attenuated FOLFIRINOX chemotherapy in patients over 65 years with advanced pancreatic adenocarcinoma. Journal of Clinical Oncology. 2015; 33(3_suppl): 468.
    CrossRef
  19. James E, Yao X, Cong X, et al. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 2014; 32(3_suppl): 256.
    CrossRef
  20. Allema JH, Reinders ME, van Gulik TM, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg. 1994; 81(11): 1642–1646.
    PubMed
  21. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997; 15(3): 928–937.
    CrossRefPubMed
  22. Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001; 5(1): 27–35.
    PubMed
  23. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009; 16(7): 1727–1733.
    CrossRefPubMed
  24. Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging. 1996; 21(3): 202–206.
    PubMed
  25. Katz MHG, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013; 20(8): 2787–2795.
    CrossRefPubMed
  26. Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008; 206(5): 833–846.
    CrossRefPubMed
  27. Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011; 150(3): 466–473.
    CrossRefPubMed
  28. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7(4): e1000267.
    CrossRefPubMed
  29. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014; 19(3): 266–274.
    CrossRefPubMed
  30. Kim HJ, Czischke K, Brennan MF, et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg. 2002; 6(5): 763–769.
    PubMed
  31. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002; 52(5): 1293–1302.
    PubMed
  32. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009; 27(33): 5660–5669.
    CrossRefPubMed
  33. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-fu) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study [Abstract]. J Clin Oncol. 2006; 24(Suppl. 18; A-4008): 180.
  34. Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011; 29(31): 4105–4112.
    CrossRefPubMed
  35. Ben-Josef E. A Phase II randomized trial evaluating the addition of high or standard intensity radiation to gemcitabine and nab-paclitaxel for locally advanced pancreatic cancer. RTOG 1201 11.03.2014.
  36. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25(3): 326–331.
    CrossRefPubMed
  37. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110(1): 47–55.
    CrossRefPubMed
  38. Zhu CP, Shi J, Chen YX, et al. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011; 99(2): 108–113.
    CrossRefPubMed
  39. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013; 14(4): 317–326.
    CrossRefPubMed
  40. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010; 78(3): 735–742.
    CrossRefPubMed
  41. Lominska CE, Unger K, Nasr NM, et al. Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas. Radiat Oncol. 2012; 7: 74.
    CrossRefPubMed
  42. Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013; 86(3): 516–522.
    CrossRefPubMed
  43. Tozzi A, Comito T, Alongi F, et al. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol. 2013; 8: 148.
    CrossRefPubMed
  44. Gurka MK, Kim C, He AR, et al. Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Am J Clin Oncol. 2017; 40(2): 152–157.
    CrossRefPubMed
  45. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121(7): 1128–1137.
    CrossRefPubMed
  46. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 58(4): 1017–1021.
    CrossRefPubMed
  47. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005; 63(2): 320–323.
    CrossRefPubMed
  48. Schellenberg D, Kim J, Christman-Skieller C, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; 72(3): 678–686.
    CrossRefPubMed
  49. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27(11): 1806–1813.
    CrossRefPubMed
  50. Polistina F, Costantin G, Casamassima F, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010; 17(8): 2092–2101.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl